Ablynx has granted an exclusive license to its anti-RANKL Nanobody, ALX-0141, to Eddingpharm, a Chinese specialty pharmaceutical company. Eddingpharm will develop and commercialize ALX-0141 in China, Hong Kong and Macao Special Administrative Regions, and Taiwan, for all indications, including osteoporosis and bone metastases.   Eddingpharm will be responsible for clinical development, registration and commercialization of anti-RANKL Nanobody therapeutics. Ablynx will have access to the data gen...